Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with probiotics (very low certainty).
It is very uncertain whether prebiotics changes withdrawals due to adverse events (4 weeks) compared with synbiotics (very low certainty).
Cerebrolysin or Cerebrolysin‐like agents showed no clear difference in total number of people with adverse events, compared with placebo (low certainty).
It is very uncertain whether insulin analogues changes any adverse events other than hypoglycaemia compared with biphasic insulin (very low certainty).
The review found no eligible studies for this question.
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Blue light showed no clear difference in any adverse events (up to 90 days; MCID 5%) compared with white light (low certainty).
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
It is very uncertain whether group B antipsychotic drugs: amisulpiride + needs‐focused intervention changes adverse effects: suicidal thoughts (events) compared with needs‐focused intervention (very low certainty).
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
Taxane followed by anthracyclines showed no clear difference in adverse events: neurotoxicity (grade 3/4) ( compared with anthracyclines followed by taxane (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Metformin probably leads to higher adverse events (gastrointestinal) per woman compared with placebo or no treatment (moderate certainty).
It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).